Investor’s Alert: Oracle Corporation (ORCL), Corning Incorporated (GLW), Bristol-Myers Squibb Company (BMY)

Oracle Corporation (ORCL) continued its upward trend with the stock climbing 0.43% or $0.18 to close the day at $41.59 on lower than average trading volume of 10.13M shares, compared to its three month average trading volume of 12.56M. The Redwood City California 94065 based company has been outperforming the application software companies by 6.4991% for last three months and its recent gains have pushed the stock slightly up 8.59% YTD, versus the application software industry which is up 10.74% for the same period. The RSI of 75.69 indicates the stock is overbought at the current levels, sell for now.

Oracle Corporation develops, manufactures, markets, sells, hosts, and supports database and middleware software, application software, cloud infrastructure, hardware systems, and related services worldwide. It offers services in three primary layers of the cloud: Software as a Service, Platform as a Service, and Infrastructure as a Service. The company licenses its Oracle Database software, which enables storage, retrieval, and manipulation of various forms of data; and Oracle Fusion Middleware software to build, deploy, secure, access, and integrate business applications, as well as automate their business processes. It also provides a range of software for mobile computing to address the development needs of businesses; and Java, a software development language. In addition, the company offers application software, such as human capital and talent management, customer experience and customer relationship management, financial management and governance, risk and compliance, procurement, project portfolio management, supply chain management, business analytics and enterprise performance management, and industry-specific application software. Further, it offers hardware systems products, such as Oracle Engineered Systems, servers, storage, networking, industry specific hardware, virtualization software, operating systems, management software, and related hardware services. Additionally, the company offers customers with rights to software product upgrades and maintenance releases, patches released, and Internet access to technical content, as well as Internet and telephone access to technical support personnel. The company also provides consulting services, such as IT strategy alignment, enterprise architecture planning and design, initial product implementation and integration, and ongoing product enhancement and upgrade; customer support services; and education services. Oracle Corporation was founded in 1977 and is headquartered in Redwood City, California.

Corning Incorporated (GLW) had a active trading with around 9.93M shares changing hands compared to its three month average trading volume of 7.08M. The stock traded between $27.38 and $27.88 before closing at the price of $27.71 with 1.28% change on the day. The Corning New York 14831 based company is currently trading 59.57% above its 52 week low of $17.69 and 0.76% above its 52 week high of $27.88. Both the RSI indicator and target price of 75.39 and $26.5 respectively, lead us to believe that it could drop over the coming weeks.

Corning Incorporated manufactures and sells specialty glasses, ceramics, and related materials in North America, the Asia Pacific, Europe, and internationally. The company operates through five segments: Display Technologies, Optical Communications, Environmental Technologies, Specialty Materials, and Life Sciences. The Display Technologies segment manufactures glass substrates for liquid crystal displays (LCDs) used in LCD televisions, notebook computers, and flat panel desktop monitors. The Optical Communications segment manufactures optical fiber and cable; and hardware and equipment products comprising cable assemblies, fiber optic hardware and connectors, optical components and couplers, closures, network interface devices, and other accessories for various carrier network applications. This segment also offers subscriber demarcation, connection and protection devices, passive solutions, and outside plant enclosures; and coaxial RF interconnects for the cable television industry and microwave applications. The Environmental Technologies segment manufactures ceramic substrates and filter products for emissions control in mobile and stationary, and gasoline and diesel applications. The Specialty Materials segment manufactures products that provide approximately 150 material formulations for glass, glass ceramics, and fluoride crystals. The Life Sciences segment manufactures and supplies scientific laboratory products consisting of consumables, such as plastic vessels, specialty surfaces, and media, as well as general labware and equipment for cell culture research, bioprocessing, genomics, drug discovery, microbiology, and chemistry; and develops and produces technologies for biologic drug production markets. The company was formerly known as Corning Glass Works and changed its name to Corning Incorporated in April 1989. Corning Incorporated was founded in 1851 and is headquartered in Corning, New York.

Bristol-Myers Squibb Company (BMY) traded within a range of $53.92 to $55.16 after opening the day at $55.08. The company has seen its stock decrease in value by -6.51% so far this year. The stock was down close to -1.36% on light volume in last trading session and closed at $54.28 per share. After the recent fall, the stock is currently holding -28.66% below its 52 week high of $77.12 and 17.97% above its 12-month low of $46.01. The shares are down by over -3.62% in the last three months, and the RSI indicator value of 56.66 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

 

Stocks Buzz: Northern Trust Corporation (NTRS), Bristol-Myers Squibb Company (BMY), NextEra Energy, Inc. (NEE)

Northern Trust Corporation (NTRS) continued its upward trend with the stock climbing 1.51% or $1.3 to close the day at $87.58 on light trading volume of 1.26M shares, compared to its three month average trading volume of 1.37M. The Chicago Illinois 60603 based company has been outperforming the asset management group over the past 52 weeks, with the stock gaining 53.5%, compared to the industry which has advanced 33.47% over the same period. With RSI of 61.01, the stock should still continue to rise and get closer to its one year target estimate of $89.31, making it a hold for now.

Northern Trust Corporation, a financial holding company, provides asset servicing, fund administration, asset management, fiduciary, and banking solutions for corporations, institutions, families, and individuals worldwide. It operates through two segments, Corporate & Institutional Services (C&IS) and Wealth Management. The C&IS segment offers asset servicing and related services, including global custody, fund administration, investment operations outsourcing, investment management, investment risk and analytical services, employee benefit services, securities lending, foreign exchange, treasury management, brokerage services, transition management services, banking, and cash management services. This segment provides services to corporate and public retirement funds, foundations, endowments, fund managers, insurance companies, sovereign wealth funds, and other institutional investors. The Wealth Management segment offers trust, investment management, custody, and philanthropic services; financial consulting; guardianship and estate administration; family business consulting; family financial education; brokerage services; and private and business banking. This segment serves high-net-worth individuals and families, business owners, executives, professionals, retirees, and established privately-held businesses. The company also provides asset management services, such as active, passive, and engineered equity; active and passive fixed income; cash management; alternative asset classes comprising private equity and hedge funds of funds; and multi-manager advisory services and products through separately managed accounts, bank common and collective funds, registered investment companies, exchange traded funds, non-U.S. collective investment funds, and unregistered private investment funds. In addition, it offers overlay services and other risk management services. Northern Trust Corporation was founded in 1889 and is based in Chicago, Illinois.

Bristol-Myers Squibb Company (BMY) grew with the stock adding 3.23% or $1.68 to close at $53.71 on active trading volume of 19.78M compared its three months average trading volume of 11.68M. The New York New York 10154 based company operating under the Drug Manufacturers – Major industry has been trending down for the last 52 weeks, with the shares price now -11.46% down for the period and down by -7.49% so far this year. With price target of $55.18 and a 16.74% rebound from 52-week low, Bristol-Myers Squibb Company has plenty of upside potential, making it a hold with a view buy.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

NextEra Energy, Inc. (NEE) managed to rebound with the stock declining 0% or $0 to close the day at $126 on lower than average trading volume of 1.61M shares, compared to its three month average trading volume of 2.17M. The Juno Beach Florida 33408 based company has been outperforming the electric utilities companies by 11.7501% for last three months and its recent gains have pushed the stock slightly up 5.47% YTD, versus the electric utilities industry which is up 1.73% for the same period. The RSI of 69.91 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

NextEra Energy, Inc., through its subsidiaries, generates, transmits, and distributes electric energy in the United States and Canada. The company generates electricity from gas, oil, solar, coal, petroleum coke, nuclear, and wind sources. As of December 31, 2015, it served approximately 9.5 million people through approximately 4.8 million customer accounts in the east and lower west coasts of Florida. The company had approximately 46,400 megawatts of generating capacity. It also leases fiber-optic network capacity and dark fiber to telephone, wireless, and Internet companies. The company was formerly known as FPL Group, Inc. and changed its name to NextEra Energy, Inc. in 2010. NextEra Energy, Inc. was founded in 1984 and is headquartered in Juno Beach, Florida.

 

Stocks in Focus: Bristol-Myers Squibb Company (BMY), Corning Incorporated (GLW), AbbVie Inc. (ABBV)

Bristol-Myers Squibb Company (BMY) had a active trading with around 5.84M shares changing hands compared to its three month average trading volume of 11.97M. The stock traded between $51.52 and $51.97 before closing at the price of $51.65 with 0.27% change on the day. The New York New York 10154 based company is currently trading 12.26% above its 52 week low of $46.01 and -32.12% below its 52 week high of $77.12. Both the RSI indicator and target price of 46.4 and $55.18 respectively, lead us to believe that it should be put on hold over the coming weeks.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Corning Incorporated (GLW) failed to extend gains with the stock declining -0.37% or $-0.1 to close the day at $26.7 on light trading volume of 5.81M shares, compared to its three month average trading volume of 7.25M. The Corning New York 14831 based company has been outperforming the diversified electronics group over the past 52 weeks, with the stock gaining 53.83%, compared to the industry which has advanced 45.27% over the same period. With RSI of 65.39, the stock should still continue to rise and get closer to its one year target estimate of $26.5, making it a hold for now.

Corning Incorporated manufactures and sells specialty glasses, ceramics, and related materials in North America, the Asia Pacific, Europe, and internationally. The company operates through five segments: Display Technologies, Optical Communications, Environmental Technologies, Specialty Materials, and Life Sciences. The Display Technologies segment manufactures glass substrates for liquid crystal displays (LCDs) used in LCD televisions, notebook computers, and flat panel desktop monitors. The Optical Communications segment manufactures optical fiber and cable; and hardware and equipment products comprising cable assemblies, fiber optic hardware and connectors, optical components and couplers, closures, network interface devices, and other accessories for various carrier network applications. This segment also offers subscriber demarcation, connection and protection devices, passive solutions, and outside plant enclosures; and coaxial RF interconnects for the cable television industry and microwave applications. The Environmental Technologies segment manufactures ceramic substrates and filter products for emissions control in mobile and stationary, and gasoline and diesel applications. The Specialty Materials segment manufactures products that provide approximately 150 material formulations for glass, glass ceramics, and fluoride crystals. The Life Sciences segment manufactures and supplies scientific laboratory products consisting of consumables, such as plastic vessels, specialty surfaces, and media, as well as general labware and equipment for cell culture research, bioprocessing, genomics, drug discovery, microbiology, and chemistry; and develops and produces technologies for biologic drug production markets. The company was formerly known as Corning Glass Works and changed its name to Corning Incorporated in April 1989. Corning Incorporated was founded in 1851 and is headquartered in Corning, New York.

AbbVie Inc. (ABBV) shares were down in last trading by -0.69% to $60.42. It experienced lighter than average volume on day. The stock decreased in value by almost -0.41% over the past week and fell -1.18% in the past month. It is currently trading -1.29% below its 50 day moving average and -1.52% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -9.58% decrease in value from its one year high of $68.12. The RSI indicator value of 42.55, lead us to believe that it is a hold for now.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; Alvine Pharmaceuticals, Inc.; and Zebra Biologics Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.

 

Worth Watching Stocks: Host Hotels & Resorts, Inc. (HST), Bristol-Myers Squibb Company (BMY), Activision Blizzard, Inc. (ATVI)

Host Hotels & Resorts, Inc. (HST) saw its value increase by 1.78% as the stock gained $0.32 to finish the day at a closing price of $18.33. The stock was higher in trading and has fluctuated between $13.66-$19.51 per share for the past year. The shares, which traded within a range of $17.86 to $18.39 during the day, are up by 18.24% in the past three months and up by 3.49% over the past six months. It is currently trading 0.86% above its 20 day moving average and 0.11% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $18.18 a share over the next twelve months. The current relative strength index (RSI) reading is 51.14.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Host Hotels & Resorts, Inc. is a publicly owned real estate investment trust (REIT). The firm primarily engages in the ownership and operation of hotel properties. It invests in the real estate markets of United States. It also invests in Canada, Mexico, Chile, the United Kingdom, Italy, Spain, and Poland. The firm primarily invests in luxury and upper upscale hotels. It was formerly known as Host Marriott Corporation. Host Hotels & Resorts, Inc. was founded in 1927 and is based in Bethesda, Maryland.

Bristol-Myers Squibb Company (BMY) shares were up in last trading by 0.66% to $52. It experienced lighter than average volume on day. The stock increased in value by almost 5.5% over the past week and fell -12.94% in the past month. It is currently trading -6.03% below its 50 day moving average and -14.72% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -31.66% decrease in value from its one year high of $77.12. The RSI indicator value of 48.41, lead us to believe that it is a hold for now.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Activision Blizzard, Inc. (ATVI) traded within a range of $39.15 to $40.12 after opening the day at $40.1. The company has seen its stock increase in value by 8.53% so far this year. The stock was down close to -2.15% on active volume in last trading session and closed at $39.19 per share. After the recent fall, the stock is currently holding -13.96% below its 52 week high of $45.55 and 49.15% above its 12-month low of $26.49. The shares are down by over -4.62% in the last three months, and the RSI indicator value of 50.67 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Activision Blizzard, Inc. develops and publishes online, personal computer (PC), video game console, handheld, mobile, and tablet games. The company operates through two segments, Activision Publishing, Inc. and Blizzard Entertainment, Inc. The company develops, publishes, and sells interactive software products and content through retail channels or digital downloads; and downloadable content to a range of gamers. It also publishes subscription-based massively multiplayer online role-playing games; and strategy and role-playing games. In addition, the company maintains a proprietary online gaming service, Battle.net that facilitates the creation of user generated content, digital distribution, and online social connectivity in its games. Further, it engages in creating original film and television content; and provides warehousing, logistical, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company serves retailers and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, game specialty stores, and consumers through third-party distribution, licensing arrangements, and direct digital purchases in the United States, Canada, Canada, the United Kingdom, France, Germany, Ireland, Italy, Sweden, Spain, the Netherlands, Australia, South Korea, China, and internationally. Activision Blizzard, Inc. is headquartered in Santa Monica, California.

 

Trader’s Buzzers: Bristol-Myers Squibb Company (BMY), PayPal Holdings, Inc. (PYPL), Boston Scientific Corporation (BSX)

Bristol-Myers Squibb Company (BMY) traded within a range of $50.56 to $51.09 after opening the day at $50.65. The company has seen its stock decrease in value by -12.09% so far this year. The stock was up close to 0.51% on light volume in last trading session and closed at $51.04 per share. After the recent gain, the stock is currently holding -32.92% below its 52 week high of $77.12 and 10.93% above its 12-month low of $46.01. The shares are up by over 2.32% in the last three months, and the RSI indicator value of 43.13 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

PayPal Holdings, Inc. (PYPL) continued its upward trend with the stock climbing 0.38% or $0.15 to close the day at $39.74 on active trading volume of 8.17M shares, compared to its three month average trading volume of 7.19M. The San Jose California 95131 based company has been outperforming the credit services group over the past 52 weeks, with the stock gaining 13.32%, compared to the industry which has advanced 28.93% over the same period. With RSI of 41.48, the stock should still continue to rise and get closer to its one year target estimate of $46.83, making it a hold for now.

PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants worldwide. It enables businesses of various sizes to accept payments from merchant Websites, mobile devices, and applications, as well as at offline retail locations through a range of payment solutions, including PayPal, PayPal Credit, Braintree, Venmo, and Xoom products. The company’s platform allows customers to pay and get paid, transfer and withdraw funds to their bank accounts, and hold balances in their PayPal accounts in various currencies. PayPal Holdings, Inc. was founded in 1998 and is headquartered in San Jose, California.

Boston Scientific Corporation (BSX) dropped $-0.08 to close the day at a new closing price of $25.14, a -0.32% decrease in value from its previous closing price that moved the stock 60.43% above its 52 week low of $16.25. A total of 8.11M shares exchanged hands during the day compared with its three month average trading volume of 8.57M. The stock, which fluctuated between $24.85 and $25.18 during the day, currently situated -0.48% below its 52 week high. The stock is up by 14.01% in the past one month and up by 16.71% over the past three months. With a one year target estimate of $27.69 and RSI of 79.25, the stock still has upside potential, making it a sell for now.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

 

Stocks in Review: Merck & Co., Inc. (MRK), CVS Health Corporation (CVS), Bristol-Myers Squibb Company (BMY)

Merck & Co., Inc. (MRK) traded within a range of $62.53 to $64.21 after opening the day at $62.64. The company has seen its stock increase in value by 9.02% so far this year. The stock was up close to 3.35% on active volume in last trading session and closed at $64.18 per share. After the recent gain, the stock is currently holding -1.2% below its 52 week high of $65.46 and 38.11% above its 12-month low of $47.97. The shares are up by over 9.06% in the last three months, and the RSI indicator value of 66.46 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments for otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company has collaboration agreements with Adaptimmune Therapeutics plc and Agenus; and a research agreement with Proteros Biostructures to develop molecule compounds for various cancer treatments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

CVS Health Corporation (CVS) continued its downward trend with the stock declining -4.07% or $-3.17 to close the day at $74.8 on light trading volume of 18.76M shares, compared to its three month average trading volume of 8.66M. The Woonsocket Rhode Island 02895 based company has been underperforming the health care plans group over the past 52 weeks, with the stock losing -20.03%, compared to the industry which has advanced 14.32% over the same period. With RSI of 31.42, the stock should still continue to rise and get closer to its one year target estimate of $87.95, making it a hold for now.

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order and specialty pharmacy services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services. This segment serves employers, insurance companies, unions, government employee groups, health plans, managed Medicaid plans and plans offered on public and private exchanges, other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS Pharmacy, CVS Specialty, Accordant, SilverScript, NovoLogix, Coram, Navarro Health Services, and Advanced Care Scripts names. As of December 31, 2015, it operated 24 retail specialty pharmacy stores, 11 specialty mail order pharmacies and 5 mail order dispensing pharmacies, and 83 branches for infusion and enteral services. The Retail/LTC segment sells prescription drugs, over-the-counter drugs, beauty products and cosmetics, personal care products, convenience foods, seasonal merchandise, and greeting cards, as well as provides photo finishing services. It operates 9,655 retail stores in 49 states, the District of Columbia, Puerto Rico, and Brazil primarily under the CVS Pharmacy, CVS, Longs Drugs, Navarro Discount Pharmacy, and Drogaria Onofre names; online retail pharmacy Websites; and 32 onsite pharmacy stores, long-term care pharmacy operations, and retail health care clinics. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1892 and is headquartered in Woonsocket, Rhode Island.

Bristol-Myers Squibb Company (BMY) gained $1.21 to close the day at a new closing price of $50.5, a 2.45% increase in value from its previous closing price that moved the stock 9.76% above its 52 week low of $46.01. A total of 18.59M shares exchanged hands during the day compared with its three month average trading volume of 12.23M. The stock, which fluctuated between $49.27 and $50.89 during the day, currently situated -33.63% below its 52 week high. The stock is down by -14.49% in the past one month and up by 0.07% over the past three months. With a one year target estimate of $59.06 and RSI of 40.35, the stock still has upside potential, making it a hold for now.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

 

Stocks Trend Analysis: Bristol-Myers Squibb Company (BMY), General Dynamics Corporation (GD), Northrop Grumman Corporation (NOC)

Bristol-Myers Squibb Company (BMY) continued its upward trend with the stock climbing 0.97% or $0.47 to close the day at $49.16 on active trading volume of 15.01M shares, compared to its three month average trading volume of 12.05M. The New York New York 10154 based company has been underperforming the drug manufacturers – major group over the past 52 weeks, with the stock losing -17.15%, compared to the industry which has advanced 5.31% over the same period. With RSI of 33.3, the stock should still continue to rise and get closer to its one year target estimate of $59.06, making it a hold for now.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

General Dynamics Corporation (GD) retreated with the stock falling -0.76% or $-1.39 to close at $181.08 on active trading volume of 2.24M compared its three months average trading volume of 1.67M. The Falls Church Virginia 22042 based company operating under the Aerospace/Defense Products & Services industry has been trending up for the last 52 weeks, with the shares price now 38.37% up for the period and up by 5.33% so far this year. With price target of $195.72 and a 47.04% rebound from 52-week low, General Dynamics Corporation has plenty of upside potential, making it a hold with a view buy.

General Dynamics Corporation operates as an aerospace and defense company worldwide. It operates through four business groups: Aerospace; Combat Systems; Information Systems and Technology; and Marine Systems. The Aerospace group designs, develops, manufactures, and outfits business-jet aircraft; provides aircraft services, such as maintenance, repair, aircraft management, charter, fixed-base operational, and staffing services; and performs aircraft completion services for other original equipment manufacturers. The Combat Systems group is involved in the design, development, production, modernization, and sustainment of combat vehicles, weapons systems, and munitions. This group offers wheeled combat and tactical vehicles; main battle tanks and tracked combat vehicles; armaments; and maintenance and logistics support and sustainment services. The Information Systems and Technology group provides technologies, products, and services that support a range of military, federal/civilian, state, local, and commercial customers. This group offers information technology solutions and mission support services; communication, command-and-control, and computer mission systems; and imagery, signals, and multi-intelligence systems for customers in the defense sector, intelligence and homeland security communities, and the United States allies. The Marine Systems group designs, constructs, and repairs surface ships and submarines for the United States Navy and Jones Act ships for commercial customers. This group offers nuclear-powered surface combatants, auxiliary and combat-logistics ships, and commercial product carriers and containerships; and provides design and engineering support services, as well as overhaul, repair, and lifecycle support services. The company was founded in 1899 and is based in Falls Church, Virginia.

Northrop Grumman Corporation (NOC) continued its downward trend with the stock declining -0.17% or $-0.4 to close the day at $229.08 on higher than average trading volume of 1.5M shares, compared to its three month average trading volume of 1.19M. The Falls Church Virginia 22042 based company has been outperforming the aerospace/defense – major diversified companies by 0.6243% for last three months and its recent gains have offset losses to -1.5% YTD, versus the aerospace/defense – major diversified industry which is down -1.67% for the same period. The RSI of 38.59 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Northrop Grumman Corporation, a security company, provides systems, products, and solutions in aerospace, electronics, information systems, and technical service areas to government and commercial customers worldwide. The company’s Aerospace Systems segment designs, develops, integrates, and produces manned aircraft, unmanned systems, spacecraft, high-energy laser systems, microelectronics, and other systems and subsystems. This segment sells its products primarily to government agencies for use in various areas, including intelligence, surveillance, and reconnaissance; communications; battle management; strike operations; electronic warfare; earth observation; satellite communications; space science; and space exploration. Its Electronic Systems segment offers solutions for sensing, understanding, anticipating, and controlling the operating environment to military, civil, and commercial customers. This segment provides various defense electronics and systems, airborne fire control radars, situational awareness systems, early warning systems, electronic warfare systems, air defense radars and management systems, navigation systems, communications systems, marine power and propulsion systems, space systems, and logistics services. The company’s Information Systems segment offers advanced solutions for Department of Defense, national intelligence, federal civilian, state, international, and commercial customers. This segment provides products and services primarily in the fields of command and control, communications, cyber, air and missile defense, intelligence processing, civil security, health information technology, and government support systems. Its Technical Services segment provides logistics, modernization, and sustainment services; and other advanced technology and engineering services, including space, missile defense, nuclear security, training, and simulation services. The company was founded in 1939 and is based in Falls Church, Virginia.

 

3 Stocks to Watch For: Pfizer Inc. (PFE), QUALCOMM Incorporated (QCOM), Bristol-Myers Squibb Company (BMY)

Pfizer Inc. (PFE) saw its value increase by 0.45% as the stock gained $0.14 to finish the day at a closing price of $31.42. The stock was lighter in trading and has fluctuated between $28.25-$37.39 per share for the past year. The shares, which traded within a range of $31.26 to $31.54 during the day, are down by -2.06% in the past three months and down by -12.74% over the past six months. It is currently trading -3.07% below its 20 day moving average and -2.35% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $37.52 a share over the next twelve months. The current relative strength index (RSI) reading is 38.11.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A.; and a research and development agreement with the National Cancer Institute. The company has a partnership with The University of Pittsburgh; and a strategic collaboration agreement with IGNITE Immunotherapy Inc. It also has a collaboration with AbCellera Biologics Inc. to discover therapeutic antibodies against undisclosed membrane protein targets. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

QUALCOMM Incorporated (QCOM) shares were up in last trading by 0.35% to $54.24. It experienced higher than average volume on day. The stock decreased in value by almost -13.74% over the past week and fell -19.35% in the past month. It is currently trading -17.32% below its 50 day moving average and -9.81% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -23.67% decrease in value from its one year high of $71.62. The RSI indicator value of 25.25, lead us to believe that it may correct downwards in the near term.

QUALCOMM Incorporated develops, designs, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, the United States, and internationally. The company operates through three segments: Qualcomm CDMA Technologies (QCT); Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on code division multiple access (CDMA), orthogonal frequency division multiple access (OFDMA), and other technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses or provides rights to use portions of its intellectual property portfolio, which include various patent rights useful in the manufacture and sale of certain wireless products comprising products implementing CDMA2000, WCDMA, CDMA TDD, and/or LTE standards, as well as their derivatives. The QSI segment invests in early-stage companies in various industries, including digital media, e-commerce, healthcare, and wearable devices for supporting the design and introduction of new products and services for voice and data communications. The company also develops and offers products for implementation of small cells; mobile health products and services; software products, and content and push-to-talk enablement services to wireless operators; and development, and other services and related products to the United States government agencies and their contractors. In addition, it licenses chipset technology and products for data centers. QUALCOMM Incorporated was founded in 1985 and is headquartered in San Diego, California.

Bristol-Myers Squibb Company (BMY) traded within a range of $47.12 to $48.62 after opening the day at $47.26. The company has seen its stock decrease in value by -17.77% so far this year. The stock was up close to 1.96% on active volume in last trading session and closed at $47.74 per share. After the recent gain, the stock is currently holding -37.26% below its 52 week high of $77.12 and 3.76% above its 12-month low of $46.01. The shares are down by over -2.51% in the last three months, and the RSI indicator value of 25.76 is bullish. They are not pointing to a rebound in the stock. We should get in as it looks to have found a bottom.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

 

Momentum Stocks: Symantec Corporation (SYMC), Sirius XM Holdings Inc. (SIRI), Bristol-Myers Squibb Company (BMY)

Symantec Corporation (SYMC) retreated with the stock falling -0.33% or $-0.09 to close at $27.26 on light trading volume of 16.58M compared its three months average trading volume of 8.03M. The Mountain View California 94043 based company operating under the Security Software & Services industry has been trending up for the last 52 weeks, with the shares price now 79.34% up for the period and up by 14.11% so far this year. With price target of $26.67 and a 86.61% rebound from 52-week low, Symantec Corporation has plenty of upside potential, making it a hold with a view buy.

Symantec Corporation, together with its subsidiaries, provides cybersecurity solutions worldwide. It operates through two segments, Consumer Security and Enterprise Security. The Consumer Security segment offers Norton-branded services that provide multi-layer security and identity protection on desktop and mobile operating systems to defend against online threats to individuals, families, and small businesses. Its Norton Security products help customers protect against complex threats and address the need for identity protection, while also managing mobile and digital data, such as personal financial records, photos, music, and videos. The Enterprise Security segment provides threat protection products, information protection products, cyber security services, and Website security offerings. Its products protect customer data from threats, such as advanced protection threats, malicious spam and phishing attacks, malware, drive-by Website infections, hackers, and cyber criminals; prevent the loss of confidential data by insiders; and help customers achieve and maintain compliance with laws and regulations. This segment delivers its solutions through various methods, such as software, appliance, software-as-a-service, and managed services. The company serves individuals, households, and small businesses; small, medium, and large enterprises; and government and public sector customers. It markets and sells its products and related services through direct sales force, e-commerce platforms, distributors, direct marketers, Internet-based resellers, system builders, Internet service providers, wireless carriers, retailers, original equipment manufacturers, and retail and online stores. Symantec Corporation was founded in 1982 and is headquartered in Mountain View, California.

Sirius XM Holdings Inc. (SIRI) had a light trading with around 16.5M shares changing hands compared to its three month average trading volume of 34.68M. The stock traded between $4.645 and $4.7 before closing at the price of $4.68 with 0.97% change on the day. The New York New York 10020 based company is currently trading 42.44% above its 52 week low of $3.29 and 0.11% above its 52 week high of $4.7. Both the RSI indicator and target price of  and $4.99 respectively, lead us to believe that it could rise over the coming weeks.

Sirius XM Holdings Inc. provides satellite radio services in the United States. The company broadcasts music plus sports, entertainment, comedy, talk, news, traffic, and weather programs, including various music genres ranging from rock, pop and hip-hop to country, dance, jazz, Latin, and classical; live play-by-play sports from principal leagues and colleges; multitude of talk and entertainment channels for various audiences; national, international, and financial news; and local traffic and weather reports for 21 metropolitan markets. It also streams music and non-music channels over the Internet; and offer applications to allow consumers to access its Internet radio service on smartphones and tablet computers. In addition, the company distributes satellite radios through the sale and lease of new vehicles; and acquires subscribers through the sale and lease of previously owned vehicles with factory-installed satellite radios. Its satellite radio systems include satellites, terrestrial repeaters, and other satellite facilities; studios; and radios. Further, the company provides satellite television services, which offer music channels on the DISH NETWORK satellite television service as a programming package; Travel Link, a suite of data services that include graphical weather, fuel prices, sports schedule and scores, and movie listings; real-time traffic services; and real-time weather services. Additionally, it offers location-based services through two-way wireless connectivity, including safety, security, convenience, maintenance and data services, remote vehicles diagnostics, stolen or parked vehicle locator services, and monitoring of vehicle emission systems. The company also sells satellite and Internet radios directly to consumers through its Website, as well as through national and regional retailers. The company was founded in 1990 and is headquartered in New York, New York. Sirius XM Holdings Inc. operates as a subsidiary of Liberty Media Corporation.

Bristol-Myers Squibb Company (BMY) saw its value increase by 1.21% as the stock gained $0.59 to finish the day at a closing price of $49.55. The stock was higher in trading and has fluctuated between $48.8-$77.12 per share for the past year. The shares, which traded within a range of $48.8 to $49.57 during the day, are up by 1.31% in the past three months and down by -33.09% over the past six months. It is currently trading -12.81% below its 20 day moving average and -12.58% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $62.34 a share over the next twelve months. The current relative strength index (RSI) reading is 25.09.The technical indicator lead us to believe the stock will reverse recent losses any time soon.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

 

Stocks Buzz: Sprint Corporation (S), Bristol-Myers Squibb Company (BMY), The Coca-Cola Company (KO)

Sprint Corporation (S) continued its upward trend with the stock climbing 0.11% or $0.01 to close the day at $9.19 on light trading volume of 17.44M shares, compared to its three month average trading volume of 19.72M. The Overland Park Kansas 66251 based company has been outperforming the wireless communications group over the past 52 weeks, with the stock gaining 264.68%, compared to the industry which has advanced 19.12% over the same period. With RSI of 68.27, the stock should still continue to rise and get closer to its one year target estimate of $7.28, making it a hold for now.

Sprint Corporation, through its subsidiaries, provides various wireless and wireline communications products and services to consumers, businesses, government subscribers, and resellers in the United States, Puerto Rico, and the U.S. Virgin Islands. The company operates in two segments, Wireless and Wireline. The Wireless segment offers wireless data communication services, including mobile productivity applications, such as Internet access, messaging, and email services; wireless photo and video offerings; location-based capabilities comprising asset and fleet management, dispatch services, and navigation tools; and mobile entertainment applications. It also provides wireless voice communications services that include local and long-distance wireless voice services, as well as voicemail, call waiting, three-way calling, caller identification, directory assistance, and call forwarding services. In addition, this segment offers voice and data services internationally through roaming arrangements; and customized wireless services to large companies and government agencies, as well as sells wireless devices, broadband devices, connected devices, and accessories to agents and other third-party distributors. The Wireline segment provides wireline voice and data communications, including domestic and international data communications using various protocols, such as multiprotocol label switching technologies, Internet protocol (IP), managed network services, Voice over IP, session initiated protocol, and traditional voice services to other communications companies, and targeted business and consumer subscribers, as well as for cable multiple system operators. Sprint Corporation offers its services under the Sprint, Boost Mobile, Virgin Mobile, and Assurance Wireless brands. The company was founded in 1899 and is headquartered in Overland Park, Kansas. Sprint Corporation is a subsidiary of SoftBank Group Corp.

Bristol-Myers Squibb Company (BMY) retreated with the stock falling -2.08% or $-1.04 to close at $48.96 on active trading volume of 17.16M compared its three months average trading volume of 11.4M. The New York New York 10154 based company operating under the Drug Manufacturers – Major industry has been trending down for the last 52 weeks, with the shares price now -20.24% down for the period and down by -15.67% so far this year. With price target of $62.34 and a 0.52% rebound from 52-week low, Bristol-Myers Squibb Company has plenty of upside potential, making it a hold with a view buy.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has clinical trial collaborations with Calithera Biosciences, Inc. and Janssen Biotech, Inc.; and a research collaboration with GeneCentric Diagnostics, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

The Coca-Cola Company (KO) continued its upward trend with the stock climbing 1.13% or $0.47 to close the day at $41.9 on higher than average trading volume of 17M shares, compared to its three month average trading volume of 13.7M. The Atlanta Georgia 30313 based company has been underperforming the beverages – soft drinks companies by 0.3027% for last three months and its recent gains have pushed the stock slightly up 1.06% YTD, versus the beverages – soft drinks industry which is up 0.86% for the same period. The RSI of 60.27 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

The Coca-Cola Company, a beverage company, manufactures and distributes various nonalcoholic beverages worldwide. The company primarily offers sparkling beverages and still beverages. Its sparkling beverages include nonalcoholic ready-to-drink beverages with carbonation, such as carbonated energy drinks, and carbonated waters and flavored waters. The company’s still beverages comprise nonalcoholic beverages without carbonation, including noncarbonated waters, flavored and enhanced waters, noncarbonated energy drinks, juices and juice drinks, ready-to-drink teas and coffees, and sports drinks. It also provides flavoring ingredients, sweeteners, beverage ingredients, and fountain syrups, as well as powders for purified water products. The Coca-Cola Company sells its products primarily under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero, Fanta, Sprite, Minute Maid, Georgia, Powerade, Del Valle, Schweppes, Aquarius, Minute Maid Pulpy, Dasani, Simply, Glacéau Vitaminwater, Bonaqua/Bonaqa, Gold Peak, FUZE TEA, Glacéau Smartwater, and Ice Dew brand names. The company offers its beverage products through a network of company-owned or controlled bottling and distribution operators, as well as through independent bottling partners, distributors, wholesalers, and retailers. The Coca-Cola Company was founded in 1886 and is headquartered in Atlanta, Georgia.